Prednisone Treatment for Vestibular Neuronitis
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of the study is to investigate the value of steroids in the treatment of vestibular neuronitis. The potential benefits of steroid therapy would be analyzed by the clinical response, self-perceived handicap and laboratory parameters.
| Condition | Intervention | Phase |
|---|---|---|
|
Vestibular Diseases Vestibular Neuronitis |
Drug: Prednisone |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Treatment |
| Official Title: | Prednisone Treatment for Vestibular Neuronitis |
- Clinical: The presence of static and dynamic nystagmus, positional and positioning nystagmus, and disequilibrium on bedside examination. [ Time Frame: 12 months ]
- Functional: Scores on the Dizziness Handicap Inventory questionnaires. [ Time Frame: 12 months ]
- Laboratory: Caloric lateralization and directional preponderance on electro-oculography (EOG). [ Time Frame: 12 months ]
| Enrollment: | 17 |
| Study Start Date: | September 2005 |
| Study Completion Date: | May 2007 |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 1
Prednisone
|
Drug: Prednisone
PO, 1 mg/kg body weight, 5 days Short tapering regimen: daily reductions in the dose, 12 days
Other Name: Prednisone
|
|
Placebo Comparator: 2
Placebo
|
Drug: Prednisone
PO, Placebo, 17 days
|
Detailed Description:
Vestibular neuronitis is the second most common cause of peripheral vestibulopathy (the first being benign paroxysmal positional vertigo) with incidence of about 3.5/100000. Currently vestibular neuronitis is explained by a viral pathogenesis.
Vestibular neuronitis is considered to have a benign course. The static rotatory vertigo and disequilibrium, present even when the patient is completely at rest, subside in most cases within a few days, and a gradual return to daily activities is the rule. However, it has been shown that there is generally incomplete restoration of peripheral function, and clinical recovery is achieved by proprioceptive and visual substitution for the unilateral vestibular deficit, combined with central vestibular compensation of the imbalance in vestibular tone. Although vestibular neuronitis is usually restricted to one attack, several studies have reported continuous or episodic vertigo or unsteadiness in 43% -53% of patients. The main residua include impaired vision and disequilibrium during walking and especially during head movement toward the affected ear. The rate of positive finding on vestibular evaluation may reach 60%. However, vestibular impairment as reflected by positive bedside testing and vestibular laboratory evaluation is not necessarily accompanied by subjective complaints and does not always reflect the level of incapacity.
The assumed HSV-1 etiology of vestibular neuronitis and the reported benefit of the combination of steroids and acyclovir in Bell's palsy suggest similar advantage in the treatment of vestibular neuronitis. Also, glucocorticoid receptors activation was reported to enhance vestibular compensation after acute peripheral vestibular insults in various animal models. A recent study investigated the effect of prednisolone versus valacyclovir and placebo on canal paresis in vestibular neuronitis patients. It was found that steroid treatment significantly improved peripheral vestibular function to the extent reflected by the caloric testing. However, bedside findings, patients' complaints and daily handicap were not evaluated. The relevance of the EOG caloric test results to clinical improvement could be argued in light of a previous report showing no correlation between EOG findings and residual symptoms in a long-term follow-up of vestibular neuronitis patients, and the finding that corticosteroid therapy had no effect on symptoms despite significant recovery of the caloric-test results.
The purpose of the study:
Prospective controlled longitudinal 12-month evaluation of the value of steroids in the treatment of vestibular neuronitis. The potential benefits of steroid therapy would be analyzed by the clinical response, self-perceived handicap and EOG laboratory parameters.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Clinical diagnosis of vestibular neuronitis.
- Documentation of unilateral reduced caloric response (caloric asymmetry >25%) on the EOG caloric study.
Exclusion Criteria:
- Complaints of new hearing loss, tinnitus, or neurological deficits.
- The presence of previously non-diagnosed sensorineural hearing loss (SNHL)
- History of vestibular dysfunction.
- Patient younger than 18 years of age.
- Known contra-indication to systemic steroids: Unbalanced hypertension, un-controlled diabetes mellitus, immunodeficiency, active peptic disease, and avascular necrosis of the femoral head.
Contacts and Locations| Israel | |
| Unit of Otolaryngology Head and Neck Surgery, Hillel Yaffe Medical Center | |
| Hadera, Israel, 38100 | |
| Otoneurolgy Unit, Lin Medical Center, Clalit Health Services | |
| Haifa, Israel, 35152 | |
| Department of Otolaryngology Head and Neck Surgery, Carmel Medical Center | |
| Haifa, Israel, 34362 | |
| Department of Otolaryngology Head and Neck Surgery, Rambam Medical Center | |
| Haifa, Israel, 31096 | |
| Principal Investigator: | Avi Shupak, MD | Carmel Medical Center and Clalit Health Services, Haifa and West Galilee |
| Principal Investigator: | Itzhak Braverman, MD | Hillel Yaffe Medical Center |
| Principal Investigator: | Avishai Golz, MD | Rambam Health Care Campus |
| Principal Investigator: | Elhanan Greenberg, ND | Carmel Medical Center |
| Study Chair: | Avi Shupak, MD | Carmel Medical Center and Clalit Health Services, Haifa and West Galilee |
More Information
Publications:
| ClinicalTrials.gov Identifier: | NCT00271791 History of Changes |
| Other Study ID Numbers: | 42352, 20050277 |
| Study First Received: | January 1, 2006 |
| Last Updated: | November 4, 2007 |
| Health Authority: | Israel: Israeli Health Ministry Pharmaceutical Administration |
Keywords provided by Carmel Medical Center:
|
Vestibular Neuronitis Vestibular Function Tests Vestibular Adaptation Steroids |
Additional relevant MeSH terms:
|
Vestibular Diseases Guillain-Barre Syndrome Neuritis Vestibular Neuronitis Polyradiculoneuropathy Autoimmune Diseases of the Nervous System Nervous System Diseases Demyelinating Diseases Peripheral Nervous System Diseases Neuromuscular Diseases Polyneuropathies Autoimmune Diseases Immune System Diseases Labyrinth Diseases Ear Diseases |
Otorhinolaryngologic Diseases Vestibulocochlear Nerve Diseases Retrocochlear Diseases Cranial Nerve Diseases Prednisone Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Pharmacologic Actions Antineoplastic Agents, Hormonal Antineoplastic Agents Therapeutic Uses Anti-Inflammatory Agents |
ClinicalTrials.gov processed this record on June 18, 2013